WuXi Biologics plans to expand its new integrated biologics conjugation solution center to include commercial manufacturing in Wuxi City, China.

Last June, WuXi Biologics announced the building of an integrated biologics conjugation solution center, including process development and clinical manufacturing for Antibody-Drug Conjugates (ADCs) drug substance and drug product. This center is expected to initiate GMP manufacturing later this year. The new 5.5-acre expansion will enable cGMP commercial manufacturing for ADCs drug substance and drug product. 

“We are quite excited to expand construction of this new integrated biologics conjugation solution center, which will further enhance our technical capabilities and manufacturing capacities in the fast-growing bioconjugation field,” said Dr. Chris Chen, chief executive officer of WuXi Biologics. “With the strength of our ONE-stop service platform covering antibody, bioconjugation drug substance and drug product, WuXi Biologics will continue enabling our global partners to develop exciting ADCs to benefit cancer patients worldwide.”

There are currently more than 20 ADCs being developed at WuXi Biologics. So far, WuXi Biologics has successfully advanced 11 ADCs projects to Investigational New Drug (IND) filing